Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $78,876.16 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Stock Up 1.3%

Shares of RXRX opened at $3.20 on Friday. The stock’s 50-day moving average price is $3.29 and its two-hundred day moving average price is $3.33. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18. The company has a market capitalization of $1.71 billion, a PE ratio of -3.08 and a beta of 1.07. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. During the same period in the previous year, the company posted ($0.41) EPS. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MCF Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $27,000. International Assets Investment Management LLC bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $31,000. Integral Investment Advisors Inc. acquired a new position in Recursion Pharmaceuticals during the first quarter worth $39,000. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $41,000. Finally, MQS Management LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $41,000. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley set a $5.30 target price on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Finally, Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.06.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.